Professor and head: Division of Pathology

Division of Pathology
University of Oslo
Rikshospitalet
0027 Oslo
Norway

Office: + (47) 23071445 / 22935620
Fax: + (47) 22505664
email: j.m.nesland@radiumhospitalet.no

---

Training: Expertise:
Micrometastasis in breast carcinoma
Diagnostic Electron MicroscopyResearch Interests:
Micrometastasis in breast carcinoma
Breast carcinoma histogenesis and molecular biologyProfessional Service:
Editor ..Other Links:

---

Selected Publications:Dhakal HP, Naume B, Synnestvedt M, Borgen E, Kaaresen R, Schlichting E,
 Wiedswang G, Bassarova A, Giercksky KE, Nesland JM.
Vascularization in primary breast carcinomas: its prognostic
significance and relationship with tumor cell dissemination.
Clin Cancer Res. 2008 Apr 15;14(8):2341-50.

Berg A, Bruland OS, Fosså SD, Nesland JM, Berner A, Schirmer C,
Lilleby W.
Disseminated tumor cells in bone marrow following definitive
radiotherapy for intermediate or high-risk prostate cancer.
Prostate. 2008 Jul 24. [Epub ahead of print]

Bergamaschi A, Tagliabue E, Sørlie T, Naume B,
 Triulzi T, Orlandi R, Russnes HG, Nesland JM, Tammi R, Auvinen P,
Kosma VM, Ménard S, Børresen-Dale AL.
Extracellular matrix signature identifies breast cancer subgroups with
 different clinical outcome.
J Pathol. 2008 Feb;214(3):357-67.

Bartkova J, Horejsí Z, Sehested M, Nesland JM, Rajpert-De Meyts E,
Skakkebaek NE, Stucki M, Jackson S, Lukas J, Bartek J.
DNA damage response mediators MDC1 and 53BP1: constitutive activation
 and aberrant loss in breast and lung cancer, but not in testicular
germ cell tumours.
Oncogene. 2007 Nov 22;26(53):7414-22. 

Langerød A, Zhao H, Borgan Ø, Nesland JM,
Bukholm IR, Ikdahl T, Kåresen R, Børresen-Dale AL, Jeffrey SS.
TP53 mutation status and gene expression profiles are powerful
prognostic markers of breast cancer.
Breast Cancer Res. 2007;9(3):R30.

Berg A, Berner A, Lilleby W, Bruland ØS, Fosså SD, Nesland JM,
 Kvalheim G.
Impact of disseminated tumor cells in bone marrow at diagnosis
in patients with nonmetastatic prostate cancer treated by definitive
radiotherapy.
Int J Cancer. 2007 Apr 15;120(8):1603-9

Holm R, Knopp S, Suo Z, Tropè C, Nesland JM
Expression of EphA2 and EphrinA-1 in vulvar carcinomas
and its relation to prognosis.
J Clin Pathol. 2007 Oct;60(10):1086-91.

Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT,
Nesland JM, Pereira EM, Lakhani SR, Schmitt FC.
Metaplastic breast carcinomas are basal-like tumours.
Histopathology. 2006 Jul;49(1):10-21.

Drageset V, Nesland JM, Erikstein B, Skovlund E, Sommer H,
Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G.
Monitoring of disseminated tumor cells in bone marrow in high-risk
breast cancer patients treated with high-dose chemotherapy.
Int J Cancer. 2006 Jun 1;118(11):2877-81

Chen D, Kennedy A, Wang JY, Zeng W, Zhao Q,
Pearl M, Zhang M, Suo Z, Nesland JM, Qiao Y, Ng AK, Hirashima N,
Yamane T, Mori Y, Mitsumata M, Ghersi G, Chen WT.
Activation of EDTA-resistant gelatinases in malignant
human tumors.
Cancer Res. 2006 Oct 15;66(20):9977-85.

Wiedswang G, Borgen E, Schirmer C, Kåresen R, Kvalheim G,
Nesland JM, Naume B.
Comparison of the clinical significance of occult tumor cells
in blood and bone marrow in breast cancer.
Int J Cancer. 2006 Apr 15;118(8):2013-9.

Furre IE, Møller MT, Shahzidi S, Nesland JM, Peng Q.
Involvement of both caspase-dependent and
-independent pathways in apoptotic induction
by hexaminolevulinate-mediated photodynamic
therapy in human lymphoma cells.
Apoptosis. 2006 Nov;11(11):2031-42.

Borgen E, Pantel K, Schlimok G, Müller P, Otte M,
Renolen A, Ehnle S, Coith C, Nesland JM, Naume B.
A European interlaboratory testing of three
well-known procedures for immunocytochemical
detection of epithelial cells in bone marrow.
Results from analysis of normal bone marrow.
Cytometry B Clin Cytom. 2006 Nov 15;70(6):400-9.

Knopp S, Holm R, Bjørge T, Tropé C, Nesland JM
Cell cycle regulation in primary vulvar
carcinomas and related lymph node metastases.
Histopathology. 2006 Sep;49(3):311-2.

Knopp S, Nesland JM, Tropé C, Holm R.
p14ARF, a prognostic predictor in
HPV-negative vulvar carcinoma.
Am J Clin Pathol. 2006 Aug;126(2):266-76.

Amarzguioui M, Peng Q, Wiiger MT, Vasovic V,
Babaie E, Holen T, Nesland JM,Prydz H.
Ex vivo and in vivo delivery of anti-tissue
factor short interfering RNA inhibits mouse
pulmonary metastasis of B16 melanoma cells.
Clin Cancer Res. 2006 Jul 1;12(13):4055-61.

Wu Q, Suo Z, Kristensen GB, Baekelandt M, Nesland JM.
The prognostic impact of EphB2/B4 expression
on patients with advanced ovarian carcinoma.
Gynecol Oncol. 2006 Jul;102(1):15-21.
Epub 2006 Feb 23.

Drageset V, Nesland JM, Erikstein B, Skovlund E,
Sommer H, Anker G, Wist E, Lundgren S, Bergh J, Kvalheim G.
Monitoring of disseminated tumor cells in bone marrow in
high-risk breast cancer patients treated with high-dose
chemotherapy.
Int J Cancer. 2006 Jun 1;118(11):2877-81

Furre IE, Shahzidi S, Luksiene Z, Møller MT,
 Borgen E, Morgan J, Tkacz-Stachowska K, Nesland JM, Peng Q.
Targeting PBR by hexaminolevulinate-mediated photodynamic therapy
 induces apoptosis through translocation of apoptosis-inducing
factor in human leukemia cells.
Cancer Res. 2005 Dec 1;65(23):11051-60.

Bartkova J, Horejsí Z, Koed K, Krämer A,
Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C,
Ørntoft T, Lukas J, Bartek J.
DNA damage response as a candidate anti-cancer barrier in
early human tumorigenesis.
Nature. 2005 Apr 14;434(7035):864-70.

Wang Y, Kristensen GB, Helland A, Nesland JM,
Børresen-Dale AL, Holm R.
Protein expression and prognostic value of genes
in the erb-b signaling pathway in advanced ovarian carcinomas.
Am J Clin Pathol. 2005 Sep;124(3):392-401.

Naume B, Wiedswang G, Borgen E, Kvalheim G, Kåresen R, Qvist H,
Janbu J, Harbitz T, Nesland JM.
The prognostic value of isolated
 tumor cells in bone marrow in breast cancer patients:
evaluation of morphological categories and the number of
clinically significant cells.
Clin Cancer Res. 2004 May 1;10(9):3091-7.